Please check your internet connection and try again.
# Olopatadine Mometasone (Ryaltris)
## Overview
Ryaltris is a fixed-dose combination nasal spray containing an H1-receptor antagonist (olopatadine hydrochloride) and a synthetic corticosteroid (mometasone furoate). It is indicated for the treatment of symptoms associated with seasonal allergic rhinitis.
## Primary Indications
* Treatment of seasonal allergic rhinitis in patients ≥12 years of age.
## Adult Dosing
* **Standard Dose:** 2 sprays in each nostril twice daily (morning and evening).
* **Total Daily Dose:** 665 mcg of olopatadine and 100 mcg of mometasone furoate.
## Pediatric Dosing
* **Adolescents (12 years and older):** Same as adult dosing (2 sprays in each nostril twice daily).
* **Children (<12 years):** Safety and efficacy have not been established.
## Dose Adjustments
* **Hepatic Impairment:** No specific adjustment provided in labeling, though use caution in severe impairment due to the mometasone component.
* **Renal Impairment:** No specific adjustment required.
## Contraindications
* Hypersensitivity to olopatadine, mometasone, or any excipients.
* Patients with recent nasal septal ulcers, nasal surgery, or nasal trauma (due to the inhibitory effect of corticosteroids on wound healing).
## Adverse Effects
* **Common:** Dysgeusia (bitter taste), epistaxis, and nasal discomfort.
* **Corticosteroid-related:** Increased risk of nasal candidiasis, septal perforation, glaucoma, cataracts, and immunosuppression (with prolonged use).
* **Systemic:** Somnolence (rare, but possible with antihistamine component).
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase systemic exposure to mometasone furoate; use with caution.
* **CNS Depressants:** Theoretically may potentiate sedation if systemic absorption occurs, though minimal with nasal administration.
## Monitoring
* Monitor for signs of nasal mucosal irritation or ulceration periodically.
* Monitor for systemic corticosteroid effects if used long-term (e.g., ocular changes, hypothalamic-pituitary-adrenal axis suppression).
* Monitor for signs of secondary nasal infections (e.g., *Candida albicans*).
## Clinical Pearls
* **Administration:** Instruct the patient to prime the pump (usually 6 sprays) before first use or if unused for 14 days.
* **Technique:** Instruct patients to shake the bottle well before each use.
* **Efficacy:** While some patients report symptom relief within 15–30 minutes, full therapeutic effect may take several days of regular use.
* **Safety:** Patients should avoid spraying directly onto the nasal septum to minimize the risk of epistaxis and perforation.
***
*Disclaimer: This information is for educational purposes only. Prescribing information, local hospital protocols, and clinical guidelines should be verified against current official resources (e.g., FDA-approved labeling or UpToDate) before making clinical decisions.*
